Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Here’s What Happened

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped up prior to trading on Tuesday . The stock had previously closed at $8.38, but opened at $8.78. Sysmex shares last traded at $8.78, with a volume of 90,388 shares.

Wall Street Analyst Weigh In

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Sysmex Stock Up 0.6%

The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12. The company has a fifty day simple moving average of $8.70 and a 200 day simple moving average of $9.35. The firm has a market capitalization of $5.51 billion, a P/E ratio of 23.03 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a return on equity of 7.28% and a net margin of 7.13%.The company had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, equities analysts expect that Sysmex Corporation ADR will post 0.5 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.